Skip to content

A Model with serum biomarkers to Predict Infliximab Response in Patients with Crohn's Disease

A Model with serum biomarkers to Predict Infliximab Response in Patients with Crohn's Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029543
Enrollment
Unknown
Registered
2020-02-03
Start date
2020-02-08
Completion date
Unknown
Last updated
2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Interventions

Gold Standard:Histology pathological examination
SES-CD endoscopy score
test&#32
for&#32
serum&#32
cytokines

Sponsors

The First Hospital Affiliated to Sun Yat sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Crohn's Disease in endoscopy, histology and imageology; 2. Moderate or severe CD patients: in active stage of disease (CDAI>150); in active stage of endoscopy (ses-CD>2 or rutgeerts score>1); 3. Injection times of inflixmab >= 4.

Exclusion criteria

Exclusion criteria: 1. Received anti TNF treatment in the past year; 2. Participate in other clinical experiments; 3. There are other contraindications, including heart failure, active tuberculosis, acute infection, active infection: hepatitis B, hepatitis C, HIV, CMV, Clostridium difficile infection; 4. Stop IFX treatment due to allergy, infusion reaction, combined infection and other factors; delay injection; no serum; loss of follow-up.

Design outcomes

Primary

MeasureTime frame
SERUM CRP;serum ESR;serum IL1;serum IL13;other serum inflammatory factors;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactZhang Shenghong

The First Hospital Affiliated to Sun Yat sen University

shenghongzhang@163.com+86 13570527027

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026